F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor.
化学药 > 有机杂环药物
卫材株式会社
北京康蒂尼药业股份有限公司; Gyre Pharmaceuticals Ltd
中国大陆
